Skip to main content
Clinical Trials/IRCT20201015049030N2
IRCT20201015049030N2
Recruiting
N/A

Comparison of the efficacy and possible side effects of high and standard doses of rifampin in the treatment of brucellosis, a randomized clinical trial

Tehran University of Medical Sciences0 sites55 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
brucellosis.
Sponsor
Tehran University of Medical Sciences
Enrollment
55
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Isolation of Brucella in culture of blood or bone marrow or other body fluids
  • Positive Brucella PCR test in blood and / or body fluids or tissue samples
  • Wright title equal to or greater than 160/1
  • The title of Combs Wright is at least two levels higher than Wright

Exclusion Criteria

  • Age less than 14 years\-
  • Intrinsic or acquired immunodeficiency
  • Simultaneous with advanced or chronic heart, lung, liver and kidney diseases
  • Pregnancy\-
  • Taking oral contraceptives
  • Consumption of phenytoin
  • History of receiving anti\-brucellosis treatment in a recent month for more than a week
  • Infection with local forms of malaria, endocarditis, spondylitis, meningitis, etc.
  • Taking antibiotics more than 7 days before the visit
  • History of allergy to doxycycline or rifampin

Outcomes

Primary Outcomes

Not specified

Similar Trials